Research PaperResearchia:202603.30053[Medicine > Open Science]
Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial
Carlos Brites
Abstract
Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial
Source: OpenAlex - Clinical Infectious Diseases (Citations: 1) PDF: N/A Original Link: https://doi.org/https://doi.org/10.1093/cid/ciag163
Submission:3/30/2026
Comments:0 comments
Subjects:Open Science; Medicine
Cite as:
Researchia:202603.30053https://www.researchia.net/explorer/790dec35-d6c0-4776-aa3f-561805461e58
Original Source:
Was this helpful?